Study Title
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)
Study Number
SCRI V940-009
Enrollment status
Open
Categories
Adjuvant Treatment for Resected NSCLC, Lung Cancer, Non-Small Cell Lung Cancer
Study Summary
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).
Study Coordinator(s)
- Angie, 309-243-3613, aearles@illinoiscancercare.com
- Heather, 309-243-3661 hthulean@illinoiscancercare.com
- Hannah, 309-243-3628 hknight@illinoiscancercare.com
- Ashton, 309-243-3611 atodd@illinoiscancercare.com
Study Link
View Study DetailsAdditional Information
Sites – Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington